Alzheon, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Alzheon, Inc. - overview
Established
2013
Location
Framingham, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2013 by CEP Martin Tolar, Ph. D. , Alzheon, Inc. operates as a provider of small-molecule inhibitors for Alzheimer's disease to patients at high genetic risk, including those with the APOE4 gene.
In June 2024, Alzheon, Inc. raised USD 100 million in Series E funding led by Alerce Medical Technology Partners. The company provides a wide range of biopharmaceutical products, such as valiltramiprosate (ALZ-801), a Phase 3 oral anti-amyloid treatment for Alzheimer's disease. Additionally, the firm also provides precision medicine approaches targeting neurodegenerative disorders, focusing on the inhibition of protein misfolding and aggregation.
Current Investors
ARCH Venture Partners, Ally Bridge Group, National Institute on Aging
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.alzheon.com/
Company Stage
Series E
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.